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Abstract Targeted nanoparticles have the potential to
deliver a large drug payload specifically to cancer cells.
Targeting requires that a ligand on the nanoparticle surface
interact with a specific membrane receptor on target cells.
However, the contribution of the targeting ligand to nano-
particle delivery is often influenced by non-specific nano-
particle uptake or secondary targeting mechanisms. In this
study, we investigate the epidermal growth factor (EGF)
receptor-targeting specificity of a nanoparticle by dual-color
fluorescent labeling. The targeted nanoparticle was a
fluorescently labeled, EGF-conjugated HDL-like peptide–
phospholipid scaffold (HPPS) and the cell lines expressed
EGF receptor linked with green fluorescent protein (EGFR-
GFP). Using LDLA7 cells partially expressing EGFR-GFP,
fluorescence imaging demonstrated the co-internalization of
EGFR-GFP and EGF-HPPS, thus validating its targeting
specificity. Furthermore, specific EGFR-mediated uptake of
the EGF-HPPS nanoparticle was confirmed using human
non-small cell lung cancer A549 cells. Subsequent confocal
microscopy and flow cytometry studies delineated how
secondary targeting mechanisms affected the EGFR targeting.
Together, this study confirms the EGFR targeting of EGF-
HPPS in lung cancer cells and provides insight on the
potential influence of unintended targets on the desired
ligand–receptor interaction.
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1 Introduction
Nanoparticle-based drug delivery is on the verge of
revolutionizing cancer therapy due to superior drug
solubility, improved serum stability, longer circulation
half-lives, better drug loading and shielding ability, and
excellent drug accumulation in tumor through the enhanced
permeability and retention effect (Brigger et al. 2002;
Petros and DeSimone 2010). External ligands, including
antibodies, proteins, peptides, aptamers, and other small
molecule ligands can be attached to nanoparticle carriers
(Brannon-Peppas and Blanchette 2004; Byrne et al. 2008;
Lammers et al. 2008), resulting in targeted nanoparticles.
When integrating a targeting ligand with a nanoparticle, the
resulting targeting efficiency may be influenced by many
factors, such as the ligand numbers (Jiang et al. 2008), the
ligand coupling method and site of ligand coupling (Zheng
et al. 2005), the interaction between the ligand and
nanoparticle (Vincent et al. 2009), as well as non-specific
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binding caused by nanoparticle itself (Chen et al. 2010).
Therefore, validation of targeting effects for a given ligand
may be difficult to resolve with traditional competition–
inhibition methods using an excess of free ligand or simple
models via positive–negative cells (Yu et al. 2010). This is
further complicated by the heterogeneous nature of tumor
cells (Poste et al. 1982). Co-expression of different
receptors or biomarkers on the cell surface may complicate
the desired ligand–receptor interaction, which may lead to
false-positive or negative results that obscure the under-
standing of how nanoparticle targeting works.
We recently reported a HDL-mimicking peptide–phos-
pholipid scaffold (HPPS) nanocarrier for the delivery of
diagnostic and therapeutic payloads (Zhang et al. 2009).
HPPS closely resembles the structure of plasma-derived
spherical HDL by replacing apoA-I protein with self-
assembled apoA-I mimetic peptides on the phospholipid
monolayer of the nanoparticle (Zhang et al. 2009). This
results in nanoparticles of well-controlled, monodispersed,
sub-30 nm size, that retain the HDL-like capacity to carry
lipophilic payloads. Perhaps equally important, HPPS
mimics the functions of plasma-derived HDL in its
pharmacokinetics and targeting specificity against scaven-
ger receptor type B1 (SR-BI), which permits excellent
delivery of the nanoparticle cargo to the target cells.
Furthermore, like HDL (Corbin et al. 2007), HPPS can be
tailored to target a receptor of choice by introducing various
targeting ligands for different cancer applications.
Epidermal growth factor receptor (EGFR), a member of
the human epidermal growth factor receptor (HER)–ErbB
family of receptor tyrosine kinases, represents an important
target for non-small cell lung cancer diagnosis and
treatment. Its activation stimulates key processes involved
in tumor growth and progression, including proliferation,
angiogenesis, invasion, and metastasis. Therefore, EGFR
has become an attractive target for nanoparticle-based lung
cancer detection and treatment (Doroshow 2005; Gatzemeier
2003). Many EGFR-specific targeting ligands (antibodies,
single chain antibody fragments, affibodies, recombinant
epidermal growth factor (EGF), EGF peptide mimetics, etc.)
have been developed and used to target nanoparticle carriers
to EGFR (Dechant et al. 2007; Nakamura et al. 2005; Reilly
et al. 2000; Senekowitsch-Schmidtke et al. 1996; Tolmachev
et al. 2009) with various degrees of success. Targeting
nanoparticles to EGFR in lung cancer provides a desirable
model to study the complexities of ligand/nanoparticle–
receptor interactions. Previously, we have successfully
developed an EGF-conjugated HPPS nanoparticle and tested
its targeting to cancer cells in vitro and in vivo (Zhang et al.
2010). The objective of this study is to take advantage of this
already established targeted nanoparticle model to systemati-
cally investigate the receptor specific uptake of EGF-
conjugated nanoparticles in lung cancer cells, thus providing
valuable insight on the potential impact of tumor cell
heterogeneity on the targeting specificity of nanoparticle
carriers.
2 Materials and methods
2.1 Preparation of EGF-conjugated HPPS nanoparticle
Human EGF was obtained from R&D Systems, Inc. (USA).
EGF-HPPS was generated as previously described (Zhang
et al. 2010). In brief, EGF was treated with Traut’s reagent
to make sulfhydryl-activated EGF. HPPS containing DSPE-
PEG (2000) maleimide and loaded with the near-infrared
fluorescent dye DiR-BOA was then mixed with sulfhydryl-
activated EGF at room temperature for 20 h. The EGF-
conjugated HPPS particle, termed EGF-HPPS, was subse-
quently filtered (0.2 μm) and purified by gel filtration
chromatography using the Akta FPLC system (Amersham
Biosciences, USA) equipped with a HiLoad 16/60 Super-
dex 200 pg column.
2.2 Cell culture
Cell culture media RPMI 1640 and Hams F-12, along with
fetal bovine serum (FBS) and Geneticin (G418) were
purchased from Gibco-Invitrogen Co. (USA). LdlA7 cells,
which minimally express EGFR and scavenger receptor
class B type I (EGFR−, SR-BI−), were kindly provided by
Dr. Monty Krieger (Massachusetts Institute of Technology,
Cambridge, MA). LdlA7 cells were cultured in Hams F-12
media with 2 mM L-glutamine, 100 U/ml penicillin–
streptomycin, and 5% FBS. Human lung adenocarcinoma
A549 cell line (EGFR+, SR-BI+) and human lung squamous
cell carcinoma NCL-H520 cell line (SR-BI+, EGFR−) were
purchased from the American Type Culture Collection. A549
cells and H520 cells were cultured in RPMI-1640 medium
supplemented with 10% FBS. All cells were grown at 37°C
in a humidified atmosphere containing 5% CO2.
2.3 Plasmid transfection
Plasmid transfections of pCDNA-EGFR-EGFP (provided
by Dr. Peter Verveer, Ludwig Institute for Cancer Research,
Royal Melbourne Hospital, Australia) were performed on
LDLA7 and A549 cells using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’ protocol. Trans-
fected cells were then exposure to Geneticin (800 μg/ml)
and sorted by the flow cytometry equipped with a Becton
Dickinson FACS Aria cell sorter to select the cells with
EGFR-GFP expressing.
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2.4 Confocal microscopy and flow cytometry
Cells were seeded into 8-well cover glass-bottom chambers
(Nunc Lab-Tek, Sigma-Aldrich, 2×104/well) for the con-
focal microscopy imaging and into 6-well cell culture plates
(3×105/well) for the flow cytometry study. AF555-EGF
(Alexa Fluor® 555 EGF complex, Molecular Probes, Inc.,
USA) was used as a standard probe to identify the EGFR
positive cells. Final concentration (2.5 μg/ml) of AF555-
EGF was used in confocal imaging and flow cytometry
analysis. To evaluate the uptake specificity of HPPS
particles, cells were incubated with HPPS or EGF-HPPS
with DiR-BOA concentration at 1 μM in cell culture
medium containing 10% FBS for 3 h at 37°C. The total
volume of incubation medium was 300 μl/well for confocal
imaging and 1 ml/well for flow cytometry. For the
competition assay, cells were coincubated with an 800-M
excess of HDL (1 mg/ml) or 5.6 μM EGF. Confocal
imaging was taken by Olympus FV1000 laser confocal
scanning microscopy (Olympus, Tokyo, Japan) with the
excitation wavelength of 488 (GFP), 543 (AF555), and
633 nm (DiR-BOA). For the flow cytometry study, the
fluorescence signal of cells were detected by a Dako
Cytomation MoFlo 9-color cell sorter for AF555 (ex.
543 nm) and a Beckman Coulter FC500 5-color analyzer
for GFP (ex. 488 nm) and DiR-BOA (ex. 633 nm).
3 Results and discussion
3.1 Establishing the correlation between EGFR expression
in cells and EGF uptake using fluorescence imaging
To understand the EGFR specificity of EGF-HPPS nano-
particles, two cell lines were chosen based on their
endogenous expression of EGFR (the receptor specific for
the EGF ligand) and SR-BI (the receptor with affinity for
the HPPS nanoparticle). Immunoblotting analysis showed
that LDLA7 cells expressed low levels of both EGFR and
SR-B1 (EGFR−, SR-BI−) whereas A549 cells expressed
high levels of EGFR and moderate levels of SR-B1
(EGFR+, SR-BI+; data not shown). To quantify the
correlation between EGF uptake and EGFR expression
level, a fluorescent surrogate of EGF, AF555-EGF (biotiny-
lated EGF conjugated with an Alexa Fluor 555-streptavidin)
was used to enable sensitive detection of EGFR. Meanwhile,
we transfected both LDLA7 and A549 cells with a plasmid
encoding an EGFR-GFP. The EGFR-GFP-LDLA7 cells were
established with only partial EGFR-GFP expression on
LDLA7 cells with no endogenous EGFR expression. This is
a useful model as the fluorescence of the EGFR-GFP served
as a convenient measure of EGFR expression and the partial
transfection created internal EGFR positive and negative
controls. Once the EGFR-GFP-LDLA7 cell line was estab-
lished, it was characterized using AF555-EGF together with
real-time confocal microscopy. Upon incubation with AF555-
EGF, confocal fluorescence imaging revealed the EGFR-
mediated, time-dependent formation of endocytotic vesicles
and their subsequent internalization (Fig. 1a). The highly co-
localized fluorescent signals from AF555 and GFP also
confirmed the intact EGFR function of EGFR-GFP
expressed on the LDLA7 cell surface (Fig. 1a). As shown
in Fig. 1b, cells that had high expression levels of EGFR-
GFP took up the most AF555-EGF. A strong positive linear
correlation (R2=0.98) was found between the expression
level of EGFR-GFP and the uptake of AF555-EGF (Fig. 1c).
Thus, the correlation between the differential receptor
expression levels in the partially transfected LDLA7 cells
and the ligand uptake pattern in those same cells are useful to
confirm EGFR-specific uptake. We next examined the
A549 lung cancer cells expressing EGFR-GFP. The stably
expressing EGFR-GFP-A549 cell line was established
through cell sorting where higher expression of EGFR than
native A549 cells was induced with EGFR-GFP. As
expected, AF555-EGF was internalized with strong co-
localization with the EGFR-GFP (Fig. 2a). Correlation
between EGFR-GFP expression levels and AF555-EGF
uptake in A549 cells was also observed using dual channel
analysis using flow cytometry (Fig. 2b). The co-localization
of AF555 and GFP signals clearly indicated the internaliza-
tion of AF555-EGF through EGFR-mediated endocytosis
pathway. Thus, two cell lines, EGFR-GFP-LDLA7 and
EGFR-GFP-A549, were successfully constructed and
validated for specific EGF uptake. These cell models provide
a solid framework to further analyze and validate nano-
particle targeting of EGFR expressing cells.
3.2 Evaluating the specific uptake of EGF-HPPS
using EGFR-GFP-LDLA7 and EGFR-GFP-A549 cells
A schematic depiction of EGF-HPPS is shown in Fig. 3a.
EGF was conjugated to the surface of HPPS and the
fluorescent cargo DiR-BOA was loaded into the core of
HPPS. Three-dimensional and dual-color confocal imaging
was used to evaluate the EGFR-mediated nanoparticle
endocytosis. Upon incubation with EGFR-GFP-A549 cells,
DiR-BOA from EGF-HPPS co-localized with the GFP
signal in EGFR-GFP-A549 cells (Fig. 3b). This confirmed
the uptake and co-localization of EGF-HPPS by EGFR. We
next used EGFR-GFP-LDLA7 cells to evaluate the target
specificity of EGF-HPPS (Fig. 4). When incubated with the
unconjugated HPPS nanoparticle, cells had no DiR-BOA
uptake. In contrast, incubation EGF-HPPS with EGFR-
GFP-LDLA7 cells revealed significant DiR-BOA uptake
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Fig. 1 A partial transfection
assay reveals EGRF-GFP and
EGF uptake and co-localization.
a Real-time visualization of
co-internalization of AF555-
EGF and EGFR-GFP by EGFR-
GFP-LDLA7 cells. b Visualiza-
tion of cellular uptake of
AF555-EGF by EGFR-GFP-
A549 cells. c Analysis of GFP
expression versus AF555-EGF
uptake from confocal images.
Data was acquired from 16 cells
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Fig. 2 EGF uptake in lung cancer cell lines. a Confocal images of
cellular uptake of AF555-EGF by EGFR-GFP-A549 cells. b Quanti-
fication of GFP expression versus AF555-EGF uptake by flow
cytometry. As shown from left to right, A549 cells alone (left),
EGFR-GFP-A549 cells alone (middle), and EGFR-GFP-A549 cells
treated with AF555-EGF (right), respectively
Fig. 3 EGF targeting of payload bearing nanoparticles. a Schematic figure of EGF-HPPS. EGF-HPPS consists of phospholipids, peptides,
cholesteryl oleate (CO), DiR-BOA cargo, and EGF. b Three-dimensional imaging of uptake of EGF(DiR-BOA) HPPS by EGFR-GFP-A549 cells
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(white arrow). Importantly, cells without any EGFR-GFP
expression (internal EGFR negative control) did not display
any detectable DiR-BOA uptake (blue arrows). This
demonstrates that EGF-HPPS specifically delivered its
cargo (DiR-BOA) to target cells via EGFR-mediated
endocytosis. To rule out the potential interference of
native HDL on the EGF-HPPS targeting, the same cells
were incubated with EGF-HPPS, along with excess HDL
and/or EGF. Confocal images illustrated that there was
no change to the specific uptake of EGF-HPPS in the
presence of HDL alone. However, the specific uptake of
EGF-HPPS was inhibited by addition of excess EGF.
These data confirmed the EGFR-targeting ability of
EGF-HPPS.
In a more complex scenario, H520 cells (EGFR−, SR-B1+),
A549 cells (EGFR+, SR-B1+), and EGFR-GFP-A549
(EGFR++, SR-B1+), with various EGFR expression levels
from negative, positive to strongly positive, were used to
quantify the specific uptake of EGF-HPPS. It should be
noted that both A549 and H520 cells are positive for SR-B1
receptor (SR-B1+), which has natural affinity for HDL
(Acton et al., 1996) and for apoA-1 mimetic helical peptides
(Wool et al., 2008; Zhang et al., 2010). Therefore, the
secondary targeting of SR-BI along with the targeting to
EGFR was investigated using confocal microscopy and flow
cytometry. First, EGFR-GFP-A549 cells were incubated with
EGF-HPPS alone, with excess HDL or with excess of both
HDL and EGF. As shown in Fig. 5a, the uptake of EGF-
HPPS by EGFR-GFP-A549 cells was completely inhibited
when both excess HDL and EGF were added but not with
only HDL, which is indicative of EGFR targeting. Under the
same condition when using H520 cells (EGFR−, SR-BI+),
very weak fluorescent signal was detected for EGF-HPPS
presumably due to the SR-BI pathway (Fig. 5b). This
secondary targeting was further confirmed by the diminished
signal in the presence of excess HDL (Fig. 5b). Further
Fig. 4 A partial transfection
assay validates EGFR-directed
nanoparticle uptake of EGF-





with excess of HDL, and EGF
by EGFR-GFP-LDLA7 cells.
White arrow represents specific
uptake of EGF(DiR-BOA)HPPS
through EGFR-mediated
pathway. Blue arrow indicates
the cells without EGFR-GFP
expression have no uptake of
EGF(DiR-BOA)HPPS
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evidence on the influence of secondary targeting was
obtained using flow cytometry. As shown in Fig. 5c, HPPS
(in the absence of EGF ligand) was taken up via SR-BI
pathway in H520, A549, and EGFR-GFP-A549 cells
(Fig. 5c, 1st column), but their uptake were all inhibited by
excess of HDL (Fig. 5c, 2nd column). The 6.3-fold
difference in the uptake of EGF-HPPS between A549 cells
and H520 cells (Fig. 5c, 3rd column) was probably due to
differential EGFR expression levels and the shielding of SR-
BI recognition by EGF conjugation, evidenced by a 2.2-fold
increase in EGF-HPPS uptake by A549 cells but a 2.3-fold
decrease by H520 cells (Fig. 5c, 3rd versus 1st column).
Furthermore, HDL blocking enhanced the EGF-HPPS
uptake contrast between A549 cells and H520 cells from
6.3-fold (Fig. 5c, 3rd column) to 9.7-fold (Fig. 5c, 4th
column). Next, uptake of EGF-HPPS by H520, A549, and
EGFR-GFP-A549 cells with or without excess of HDL were
evaluated at 3, 6, and 24 h after incubation (Fig. 5d and e).
At all three time points, the difference of EGF-HPPS uptake
between A549 (EGFR+) and EGFR-GFP-A549 (EGFR++)
could not be distinguished without the excess of HDL which
blocks secondary SR-BI targeting (Fig. 5d). Clear differences
only appeared after adding excess of HDL, which revealed
the pure EGFR targeting (Fig. 5e). Another interesting effect
of this secondary targeting lies in the fact both EGFR and
SR-BI contributed to the EGF-HPPS uptake. This observa-
tion could be explored for enhancing the uptake through dual
receptor coordination.
Fig. 5 EGF-HPPS as nanoprobe for targeting lung cancer cells
expressing high level of EGFR in vitro. Confocal imaging of
distinguished uptake of EGF-HPPS between: a EGFR positive A549
cells and b EGFR negative H520 cells. c Quantification of cellular
uptake of HPPS, HPPS with excess of HDL, EGF-HPPS, EGF-HPPS
with excess of HDL or EGF-HPPS with excess of HDL and EGF by
H520, A549, and EGFR-GFP-A549 cells within 3 h incubation. d
Quantification of cellular uptake of EGF-HPPS by H520, A549, and
EGFR-GFP-A549 cells during 3, 6, and 24 h incubation by flow
cytometry. e Quantification of cellular uptake of EGF-HPPS by H520,
A549, and EGFR-GFP-A549 cells with excess of HDL
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We have validated the specific uptake of EGF-HPPS
nanoparticles via the EGFR pathway as well as the
secondary targeting via SR-BI pathway using dual fluores-
cent labeling approach (labeling both the nanoparticles and
cell lines). The use of double negative LDLA7 cells
(EGFR− and SR-BI−) established a clear baseline for
EGFR-GFP partial transfection to create internal EGFR+
and EGFR− controls. On the other hand, the use of both
EGFR-GFP-A549 cells (EGFR++) and wild-type A549 cells
(EGFR+) together with the use of H520 cells (EGFR−)
allowed us to analyze the EGF/EGFR response at different
levels of EGFR expression in lung cancer cells.
In summary, this study confirmed the EGFR targeting of
EGF-HPPS in lung cancer cells. More importantly, the dual
fluorescent labeling approach (labeling both the ligand-
conjugated nanoparticle carrier and the targeted receptors
on the cells) developed in this study provides more insight
on the potential influence of secondary targets on the
intended ligand–receptor interaction. Furthermore, this
fluorescent imaging strategy may be applied for target
validation in other applications such as confirming the
putative target receptor for a ligand of interest.
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